Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Induration08.01.03.0200.021340%Not Available
Cardiac disorder02.11.01.003--Not Available
Eye movement disorder17.02.05.025; 06.05.02.0080.010670%Not Available
Ischaemia24.04.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction17.01.02.031; 15.05.06.006--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Sensation of foreign body08.01.09.0020.121639%Not Available
Obstructive airways disorder22.03.01.0110.051216%Not Available
Psychotic disorder19.03.01.002--
Sinus disorder22.04.06.0020.010670%
Increased upper airway secretion22.12.03.0070.015649%Not Available
Anaphylactoid shock24.06.02.005; 10.01.07.0040.046237%Not Available
Infusion site extravasation12.07.05.008; 08.02.05.0070.179257%
Immediate post-injection reaction10.01.03.032; 08.06.01.019--Not Available
Oropharyngeal discomfort07.05.05.008; 22.12.03.0150.063309%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.044103%
Vulvovaginal pain21.08.02.0090.007113%
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.010670%Not Available
Acute kidney injury20.01.03.0160.189927%
Use of accessory respiratory muscles22.12.02.0150.007113%Not Available
Hypoxic-ischaemic encephalopathy22.02.02.011; 24.04.06.021; 17.13.02.0060.017783%Not Available
Respiratory tract oedema22.02.07.0130.021340%Not Available
Toxicity to various agents12.03.01.046--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 12.03.01.064; 10.01.01.0210.032010%Not Available
Mouth swelling07.05.04.007; 23.04.01.020; 10.01.05.0200.049082%Not Available
Nasal pruritus22.04.03.0180.074691%Not Available
Anal incontinence17.05.01.021; 07.01.06.0290.032010%
Depersonalisation/derealisation disorder19.14.01.004--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene